Pentoxifylline in vascular pathology

Pentoxifylline in vascular pathology

A.V. Chupin¹, N.V. Pizova², D.A. Korshunov^{1 1}A.V. Vishnevsky Institute of Surgery, Moscow

²Yaroslavl State Medical University, Yaroslavl 

Atherosclerosis as a systemic disease affects large and medium arteries and becomes the cause of coronary heart disease, strokes and peripheral artery diseases (POAs). At the same time, the problem of POA is insufficiently studied and underestimated versus other atherosclerotic diseases. The detection frequency of POA and cerebrovascular diseases in one patient is quite high, since atherosclerotic diseases have similar risk factors, which determines a unified approach to patient management using non-pharmacological and pharmacological measures. Drug therapy includes the use of various drug groups, including pentoxifylline, which has long proven to be an effective, safe drug with good tolerability. The article describes the main drug effects (vasodilating, antithrombotic, endothelioprotective, immunomodulatory, etc.), allowing its use in patients with multilocus atherosclerotic vascular disease. The article also presents the clinical study results demonstrating the pentoxifylline efficacy in the treatment of patients with intermittent claudication, critical limb ischemia, coronary heart disease, cardiac failure of various etiologies, chronic and acute cerebrovascular insufficiency.

Keywords: atherosclerosis, cardiovascular diseases, peripheral artery diseases, intermittent claudication, pentoxifylline.

For citation: Chupin A.V., Pizova N.V., Korshunov D.A. Pentoxifylline in vascular pathology. RMJ. 2023;3:15–20.